We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
표시할 이벤트가 없습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 12. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
Rating & price-target changes
표시할 리서치 액션이 없습니다.
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Stored first · Google News · Yahoo Finance (English)
CSCI SEC Filings - Cosciens Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
CSCI SEC Filings - Cosciens Biopharma 10-K, 10-Q, 8-K Forms Stock Titan
Cosciens Biopharma schedules special shareholder meeting for June 17 By Investing.com - Investing.com South Africa
Cosciens Biopharma schedules special shareholder meeting for June 17 By Investing.com Investing.com South Africa
Cosciens Biopharma schedules special shareholder meeting for June 17 By Investing.com - Investing.com UK
Cosciens Biopharma schedules special shareholder meeting for June 17 By Investing.com Investing.com UK
June 17 shareholder meeting set by COSCIENS Biopharma (CSCI) - Stock Titan
June 17 shareholder meeting set by COSCIENS Biopharma (CSCI) Stock Titan
COSCIENS Biopharma Reports $1.2 Million Revenue and $5.8 Million Net Loss in First Quarter 2026 - geneonline.com
COSCIENS Biopharma Reports $1.2 Million Revenue and $5.8 Million Net Loss in First Quarter 2026 geneonline.com
COSCIENS Biopharma Inc. Reports Q1 2026 Results